INTRODUCTION
============

The incidence of IBD has been rising rapidly globally over the past few decades.[@B1] There are wide geographic variations in the incidence and prevalence of IBD, and the disease is still more prevalent in Western countries than in Asia. In Asia, IBD is a rapidly emerging disease, particularly in the more developed countries of the region.[@B2][@B3] A recent multi-country epidemiological study showed that the incidences of both CD and UC are still significantly lower in most Asian countries than in Australia.[@B4] However, there are wide variations in the incidence of IBD across different Asian countries.

Since most published epidemiological data on IBD originates from Western countries, it remains to be determined whether data published in the West can be directly translated to the Asian setting. In particular, there is a pressing need to validate whether the disease phenotypes, responses to various treatments, and complications are comparable between Asian patients and their Western counterparts.

To this end, our Asian colleagues have produced many high-quality publications on the epidemiology of IBD in Asia. A simple search of the PubMed (as in April 2015) database with the keyword \"IBD epidemiology in Asia\" yields an increasing number of publications over the past few decades ([Fig. 1](#F1){ref-type="fig"}). There were virtually no publications on this topic before the 70\'s, followed by a surge in the late 90\'s. However, many of these studies, particularly the early ones, involved small numbers of patients and were based on a few highly selected tertiary referral centers in Asia, which may limit the validity of the results when generalized to the broader region.

With the increasing number of IBD patients in Asia, better design and organization of epidemiological cohort studies are needed. This article attempts to discuss ways of optimizing IBD cohort studies, and to share our early experiences of the recently established Hong Kong IBD registry.

AIMS OF COHORT STUDIES
======================

Similar to randomized controlled studies, cohort studies are designed to address clinical questions relevant to disease pathogenesis, characteristics, or management. For IBD, common goals of cohort studies are to characterize epidemiological data on IBD patients, and to collect information on treatment responses and disease related complications and health care utilization. They are also useful in determining other aspects of disease, including various social and psychological parameters.

Prospective cohort studies are capable of obtaining bio-specimens such as colonic biopsy and fecal or blood samples for use in biobanks, which are very useful in subsequent genome-wide association studies as well as microbiota analyses.

COHORT STUDY DESIGN
===================

Cohort studies are a form of longitudinal study that attempts to analyze target outcomes in a group of individuals. The outcomes can be the occurrence of a target disease among those with exposure to certain risk factors, or the development of a complication among those with a certain disease. In either case, the incidence of disease or the relative risk of exposure can be precisely estimated. In contrast to prospective randomized clinical trials that usually involve intervention, cohort studies are usually observational in nature and patients are not randomly assigned to a specific treatment. This aspect is inferior to randomized controlled trials, as this approach may introduce bias.

The design of these observational studies could be further classified into \"prospective\" and \"retrospective\". For instance, a prospective IBD cohort enrolls all eligible IBD patients and follows them longitudinally. All relevant clinical and epidemiological information is recorded at baseline, and updated at intervals during the follow-up period. This may limit recall bias when compared to retrospective cohort studies when the target outcome has already developed. However, some information collected is still retrospectively recalled, particularly in patients with longstanding disease. An inception cohort captures all patients newly diagnosed with IBD only, which minimizes these potential recall biases due to long lag times. This is extremely useful for epidemiological studies designed to determine incidence and exposure. Due to the prospective nature of these studies, they can provide accurate relative risk or risk ratio estimation of target outcomes. Unlike randomized trials that typically assess a single primary outcome, multiple outcomes can be measured. However, inception cohort studies usually require long follow-up periods, and are generally expensive. Problems with patients being lost to follow-up can create uncertainties in data analysis and potential bias.

A retrospective cohort study is conceived after some individuals have already developed the outcomes, e.g., the occurrence of IBD or its related complications. This type of study does not require long follow-up duration and is particularly useful for rare diseases, such as IBD in Asia. These studies are also less costly than prospective cohort studies. Unlike in prospective studies, temporal relationships usually cannot be determined. It is also important to adjust for potential confounding factors in retrospective cohort studies, particularly in selecting cases and determining exposures.

IMPLEMENTATION OF PROSPECTIVE COHORT STUDIES
============================================

Although intervention is usually lacking for cohort studies, the design and execution, particularly for a prospective cohort study, is very similar to a randomized controlled trial. The effort and resources needed for this kind of study would be comparable to a prospective interventional study. A good example of a long-term cohort study is the Framingham Heart Study, which was started in 1948.[@B5] There are also many examples of long-term IBD cohort studies present in the literature ([Table 1](#T1){ref-type="table"}).[@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15] Although most of these data are from Western countries, there are a few ongoing Asian cohort studies.[@B4][@B16]

1. Data Collection
------------------

In prospective IBD cohort studies, like inception cohort studies, all patients are identified at baseline and are followed-up longitudinally for target outcomes like the development of complications, mortality, surgical resection etc. Unfortunately, some of these target outcomes may not be identified at the beginning of the study, and are sometimes only considered many years after the study has started. Hence, it is vital to carry out comprehensive and detailed planning for baseline data collection. How often this information needs to be updated is equally important. Since the frequency and extent of follow-up data collection can have major implications on resources and patient compliance, it is prudent to be realistic and practical. Due to the differences in health care systems in different countries, the availability of centralized electronic medical record systems or other similar administrative databases helps to reduce the workload of database maintenance. With long anticipated follow-up durations, mechanisms should be in place to identify patients who have been lost to follow-up due to various reasons.

2. Resources
------------

A team of dedicated IBD researchers is the most important asset of any IBD cohort study. This team should comprise gastroenterologists with a special interest in IBD, research assistants, biostatisticians, technicians, and other related health care personnel. With the many parties involved, regular meetings and progress reports are needed to update all members. A transparent and pre-defined mechanism of sharing the intellectual property obtained from this kind of cohort study, like authorships in publications and the share of patents, is also crucial to maintaining team spirit and avoiding future conflicts. It may also be necessary to establish a publication subcommittee to oversight all research-related publications. The long-term storage of bio-specimens requires proper designated storage space (or freezers) and staff, which can have long-term implications on resource utilization. It is also important to clearly define the rules and regulations governing the future usage of these bio-specimens at the beginning of the study.

As mentioned previously, obtaining adequate funding is another important task for investigators. With the long follow-up duration (sometimes up to a few decades) of cohort studies, the provision of continuous funding support can be a problem for many non-governmental sponsored registries. Hence, a realistic estimate of the sustainability of this cohort study and a frequent revision of the budget may be necessary, particularly for prospective cohort studies.

3. Regulatory Issues
--------------------

To ensure compliance with various regulatory authorities, approval from all local institutional review boards concerned should be obtained prior to the implementation of the study. This process can be very time consuming when multiple institutions are involved. Proper informed consent should also be obtained for patients enrolling in prospective studies, and particularly for studies involving the storage of patients\' clinical specimens. Special attention should also be directed to maintaining patients\' confidentially in the database. Internet security is another important issue that should not be overlooked, particularly with the use of open web-based databases. However, the use of anonymous data may pose problems in subsequent follow-up and data validation.

THE HONGKONG IBD REGISTRY
=========================

The Hong Kong IBD Registry was established in 2011 to systematically collect clinical and epidemiological data from IBD patients attending public hospitals in Hong Kong. The registry aims to fill the knowledge gap in the understanding of IBD patients and foster IBD research in Hong Kong. It is a territory-wide registry that includes all public hospitals in Hong Kong. The public hospital system is directly funded by the Hong Kong Government, and is available to all local residents at a minimal cost. It currently provides more than 90% of in-patient services in Hong Kong. The current registry covers 13 public hospitals with a catchment area of more than 7.3 million people. The registry was approved by the local Institutional Review Boards (IRBs) of each individual hospital. Funding was provided by local philanthropists and the pharmaceutical industry, both of which have no role in the daily operations of the registry. A central web-based database was used for data entry from individual participating hospitals. All patients were provided with a unique patient number such that no confidential patient information was stored in the central database.

We prospectively enrolled all patients with a confirmed diagnosis of IBD including CD, UC, and indeterminate colitis. With the help of the central computer medical record system of the Hospital Authority of Hong Kong, which essentially captured all clinical events, prescription histories, endoscopy records, and laboratory results of these patients, important clinical information could be updated periodically. As of April 2014, we collected information from more than 2,200 IBD patients. Results of some of the baseline analyses of these patients were presented in Digestive Disease Week 2015. Apart from data collection, the registry is also setting up a bio-specimen bank of blood and stool samples of IBD patients for future genomic and microbiota studies.

CONCLUSIONS
===========

It is an exciting moment for IBD research in the Asia Pacific region, where the disease is emerging rapidly. The formation of IBD study groups and local IBD registries would help to produce valuable epidemiological data on patients, and will ultimately help to transform the care of IBD patients in this region.
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###### Examples of Population-Based IBD Registries

![](ir-13-208-i001)

  Continent           Reference   Name of registry                                 Countries           Design                  Year        No. of patients
  ------------------- ----------- ------------------------------------------------ ------------------- ----------------------- ----------- -----------------
  **Europe**                                                                                                                               
                      6           Epimad registry                                  Northern France     Inception cohort        1988        18,170
                      7           EC-IBD study group                               Europe and Israel   Inception cohort        1991        1,145
                      8           Danish CD database                               Denmark             Prospective             2003        562
                      9           Swiss IBD cohort study group                     Switzerland         Prospective             2003        1,020
                      10          CESAME study group                               France              Prospective             2004        19,486
                      11          Cardiff                                          UK                  Retrospective           1986-2003   341
                      12          SPIRIT registry                                  Spain               Retrospective           1996-2009   2,107 children
  **North America**                                                                                                                        
                      13          University of Manitoba IBD research registry     Canada              Retrospective           1985        NA
                      14          Veterans Affairs                                 USA                 Retrospective           1998-2009   43,114
                      15          ImproveCareNow Collaborative for pediatric IBD   USA                 Multi-center registry   2007-2008   1,598 children
  **Asia-Pacific**                                                                                                                         
                      16          Japanese nationwide IBD registry                 Japan               Prospective             1975        NA
                      4           ACCESS study group                               Asia-Pacific        Inception cohort        2011        419
                                  Hong Kong IBD registry                           Hong Kong           Prospective             2013        2,220

EPIMAD, registre des maladies inflammatoires du tube digestif du nord-ouest de la France; EC-IBD, European collaborative study group of inflammatory bowel disease; CESAME, cancers et surrisque associé aux maladies inflammatoires intestinales en France; SPIRIT, sociedad española de gastroenterología hepatología nutrición pediátrica; ACCESS, Asia-pacific crohn\'s and colitis epidemiology study; NA, not available.
